Nashua, NH, November 20, 2024 – Consumer testing startup AcuDart Health has launched an at-home Lyme disease test with an accuracy considerably higher than that of the two-tier testing protocol recommended by the CDC, as well as tests from industry leaders CVS and Everlywell.
Low accuracy of Lyme disease tests has been an issue for decades. Many patients are routinely misdiagnosed and end up suffering for years. AcuDart tests are able to achieve higher accuracy because they look for antibodies to more species of the disease. Whereas most tests look for an immune response to only one or two species, the AcuDart Lyme disease test detects antibodies to nine Lyme-causing species.
Lyme disease, the most common tick-borne disease (TBD), is one of the fastest-growing infectious diseases in the United States. Around 476,000 people are diagnosed with Lyme annually in the US. That makes Lyme disease cases four times more common than new cases of HIV/AIDS, tuberculosis, and syphilis combined. It is caused by Borrelia burgdorferi, a type of bacteria carried by deer ticks. Lyme disease symptoms include fever, headache, fatigue, chills, joint and muscle pain.
Diagnosis of any TBD based on clinical grounds is very challenging because symptoms can mimic many other diseases. These diseases can also affect any organ of the body, including the brain and nervous system, muscles and joints, and the heart. Only with accurate and reliable testing can patients determine if they have a TBD.
In addition to Lyme, AcuDart Health has also launched tests for other common diseases including Tick-Borne Relapsing Fever (TBRF), Bartonellosis, and Babesiosis. There is also a test panel which detects all four diseases.
Key features of the AcuDart tests
- Screens for 19 markers across Lyme disease, TBRF, Babesiosis, and Bartonellosis
- Completed at home
- Fast and free FedEx shipping both ways in USA and Canada
- No doctor authorization required
- Can be purchased for others
- Five year shelf life so you can stock up
- Detects antibodies to more species than competing tests